In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...

The Business Research Company's Kadcyla Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...